1.20
-0.04 (-3.63%)
| Penutupan Terdahulu | 1.24 |
| Buka | 1.21 |
| Jumlah Dagangan | 1,466,925 |
| Purata Dagangan (3B) | 3,220,411 |
| Modal Pasaran | 948,570,496 |
| Harga / Jualan (P/S) | 1.47 |
| Harga / Buku (P/B) | 0.710 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Margin Keuntungan | -5.66% |
| Margin Operasi (TTM) | -44.79% |
| EPS Cair (TTM) | -0.060 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -13.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 37.58% |
| Nisbah Semasa (MRQ) | 2.49 |
| Aliran Tunai Operasi (OCF TTM) | -182.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -107.74 M |
| Pulangan Atas Aset (ROA TTM) | -8.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Opko Health, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.30 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 46.81% |
| % Dimiliki oleh Institusi | 30.94% |
| Julat 52 Minggu | ||
| Median | 1.50 (25.52%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barrington Research | 02 Mar 2026 | 1.50 (25.52%) | Beli | 1.24 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| PAGANELLI JOHN A | 1.12 | - | 10,000 | 11,200 |
| Jumlah Keseluruhan Kuantiti Bersih | 10,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 11,200 | |||
| Purata Pembelian Keseluruhan ($) | 1.12 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PAGANELLI JOHN A | Pengarah | 20 Mar 2026 | Beli (+) | 10,000 | 1.12 | 11,200 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism |
| 06 Jan 2026 | Pengumuman | OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |